These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 11308253)

  • 61. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
    Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
    Mitchell MS; Lund TA; Sewell AK; Marincola FM; Paul E; Schroder K; Wilson DB; Kan-Mitchell J
    Cancer Immunol Immunother; 2007 Mar; 56(3):287-301. PubMed ID: 16874487
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope.
    Thorn M; Wang M; Kløverpris H; Schmidt EG; Fomsgaard A; Wenandy L; Berntsen A; Brunak S; Buus S; Claesson MH
    Cancer Immunol Immunother; 2007 Nov; 56(11):1755-63. PubMed ID: 17464507
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
    Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
    Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA
    Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clonal heterogeneity in LFA-3 and ICAM-1 requirement for lysis by alloreactive T lymphocytes.
    Galocha B; López D; López de Castro JA
    J Immunol; 1993 Mar; 150(5):1653-62. PubMed ID: 7679690
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA; Schlom J; Abrams SI
    J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.
    Würtzen PA; Claesson MH
    Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes.
    Ciernik IF; Berzofsky JA; Carbone DP
    Clin Cancer Res; 1996 May; 2(5):877-82. PubMed ID: 9816244
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes.
    Alexander J; Oseroff C; Sidney J; Wentworth P; Keogh E; Hermanson G; Chisari FV; Kubo RT; Grey HM; Sette A
    J Immunol; 1997 Nov; 159(10):4753-61. PubMed ID: 9366399
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice.
    Men Y; Miconnet I; Valmori D; Rimoldi D; Cerottini JC; Romero P
    J Immunol; 1999 Mar; 162(6):3566-73. PubMed ID: 10092815
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
    McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
    Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice.
    Tang XD; Liang GP; Li C; Wan Y; Chen T; Chen L; Yu ST; Xiong Z; Fang DC; Wang GZ; Yang SM
    Cancer Immunol Immunother; 2010 Jul; 59(7):1041-7. PubMed ID: 20182872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes.
    Suzuki K; Sahara H; Okada Y; Yasoshima T; Hirohashi Y; Nabeta Y; Hirai I; Torigoe T; Takahashi S; Matsuura A; Takahashi N; Sasaki A; Suzuki M; Hamuro J; Ikeda H; Wada Y; Hirata K; Kikuchi K; Sato N
    J Immunol; 1999 Sep; 163(5):2783-91. PubMed ID: 10453022
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A*2402-CMVpp65 tetramer.
    Akiyama Y; Kuzushima K; Tsurumi T; Yamaguchi K
    Immunol Lett; 2004 Sep; 95(2):199-205. PubMed ID: 15388261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.